What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-03-31 compared with 2022-03-31 · 23 added, 33 removed, 0 unchanged (100% of the section changed)

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

July 13, 2021, our common stock began trading on The Nasdaq Capital Market under the symbol “UNCY.” Prior to that time, there

was no public market for our common stock.

Proceeds from Initial Public Offering

On July 15, 2021, we closed the initial public offering (“IPO”)

of our common stock pursuant to which we issued and sold 5,000,000 units at an initial public offering price of $5.00 per Unit.

the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on

Form S-1 (File No.

333-256367), which was declared effective by the SEC on July 12, 2021.

We received net proceeds of approximately

$22.3 million, after deducting underwriting discounts and commissions and offering expenses borne by us.

None of the expenses incurred

by us were direct or indirect payments to any of (i) our directors or officers or their associates, (ii) persons owning 10%

or more of our common stock, or (iii) our affiliates.

There has been no material change in the planned use of proceeds from our initial

as described in our final prospectus filed with the SEC on July 14, 2021 pursuant to Rule 424(b)(4).

Roth Capital Partners acted

as sole book-running manager for the offering.

The offering commenced on July 13, 2021 and did not terminate before all securities registered

in the registration statement were sold.

of March 4, 2022, there were 977 stockholders of record of our common stock.

The actual number of holders of our common stock is greater

than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by

brokers or held by other nominees.

This number of holders of record also does not include stockholders whose shares may be held in trust

by other entities.

have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common

stock in the foreseeable future.

We intend to retain all available funds and any future earnings to fund the development and expansion

of our business.

Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a

number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions

imposed by applicable law and other factors our board of directors deems relevant.

MARKET FOR REGISTRANT’S

COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

On July 13, 2021, our common stock began trading

on The Nasdaq Capital Market under the symbol “UNCY.” Prior to that time, there was no public market for our common stock.

As of March 28, 2023, there were 73 stockholders

of record of our common stock.

The actual number of holders of our common stock is greater than this number of record holders, and includes

stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees.

This number of

holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy

anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring

or paying any cash dividends for the foreseeable future, except that i n March 2023,we agreed with certain investors to modify our

dividend policy to state that we intend to pay dividends to all stockholders on a quarterly basis in an amount of which the aggregate

of all quarterly dividends shall equal at least seventy-five percent (75%) of our annual net cash flow from operations following the approval

of Renazorb by the FDA if obtained, and the commencement of commercial sales.

Sales of Unregistered Securities

On November 28, 2022, we issued 33,500 shares

of restricted common stock to RedChip for investor advisory services.

The foregoing issuance was

made in a transaction not involving a public offering pursuant to an exemption from the registration requirements of the Securities Act

in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity